Citation Impact
Citing Papers
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
2013 Standout
Metabolic Syndrome in Men With Prostate Cancer Undergoing Long-Term Androgen-Deprivation Therapy
2006
Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions
2007
Recurrence of Hyperprolactinemia after Withdrawal of Long-Term Cabergoline Therapy
2009
Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer
2006
Relation of Smoking With Total Mortality and Cardiovascular Events Among Patients With Diabetes Mellitus
2015
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary
2014 Standout
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Can exercise ameliorate treatment toxicity during the initial phase of testosterone deprivation in prostate cancer patients? Is this more effective than delayed rehabilitation?
2012
Effects of Monounsaturated Fatty Acids on Glycaemic Control in Patients with Abnormal Glucose Metabolism: A Systematic Review and Meta-Analysis
2011
Acromegaly
2006 Standout
Nitric oxide and atherosclerosis: An update
2006 Nobel
Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension*
2005
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
2015 Standout
Severe Hypoglycemia and Risks of Vascular Events and Death
2010 Standout
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
2016 Standout
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Psychosocial factors in medication adherence and diabetes self-management: Implications for research and practice.
2016
Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
2020
Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen‐deprivation therapy
2005
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
2012 Standout
National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants
2011 Standout
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
2014
Risk Factors for Cerebrovascular Deaths in Patients Operated and Irradiated for Pituitary Tumors
2002
Cushing's syndrome
2015 Standout
Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD
2008
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
2015
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
2015 Standout
Diabetic dyslipidaemia: from basic research to clinical practice*
2003
Prolactinomas
2010
Nitric Oxide and Peroxynitrite in Health and Disease
2007 Standout
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
2010
Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer
2004
Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline
2011 Standout
The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern
2011
Recurrence of Hyperprolactinemia after Withdrawal of Dopamine Agonists: Systematic Review and Meta-Analysis
2009
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
2013 Standout
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
2011 StandoutNobel
Androgen-deprivation Therapy and Diabetes Control Among Diabetic Men with Prostate Cancer
2013
Type 2 diabetes
2017 Standout
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
2013 Standout
Diabetes and Atherosclerosis
2002 Standout
Carboplatin: current status and future prospects
1988
Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia
2003
Type 1 diabetes
2013 Standout
Androgen-Deprivation Therapy for Nonmetastatic Prostate Cancer Is Associated With an Increased Risk of Peripheral Arterial Disease and Venous Thromboembolism
2012
What community measurements can be used to predict bone disease in patients with COPD?
2008
Increasing use of gonadotropin‐releasing hormone agonists for the treatment of localized prostate carcinoma
2005
Cancer immunotherapy comes of age
2011 StandoutNature
Endothelial function and coronary artery disease
2001
Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies
2008 Standout
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
2010
A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy
2011
Hyperprolactinemia and Prolactinomas
2008
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
Insulin Sensitivity during Combined Androgen Blockade for Prostate Cancer
2006
Adipocytokines, Obesity, and Insulin Resistance During Combined Androgen Blockade for Prostate Cancer
2008
Repertoire Enhancement with Adoptively Transferred Female Lymphocytes Controls the Growth of Pre-Implanted Murine Prostate Cancer
2012 StandoutNobel
The Human Obesity Gene Map: The 2003 Update
2004
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
2015 Standout
Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?
2012
Androgen-deprivation Therapy in Treatment of Prostate Cancer and Risk of Myocardial Infarction and Stroke: A Nationwide Danish Population-based Cohort Study
2013
Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies
2007
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
2013 Standout
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
2015 Standout
Management of Side Effects of Androgen Deprivation Therapy
2011
Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials
2011
Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
2014 Standout
Intensive Insulin Therapy in the Medical ICU
2006 Standout
Metabolic changes during gonadotropin‐releasing hormone agonist therapy for prostate cancer
2008
Activation of Oxidative Stress by Acute Glucose Fluctuations Compared With Sustained Chronic Hyperglycemia in Patients With Type 2 Diabetes
2006 Standout
Management of Diabetes and Hyperglycemia in Hospitals
2004
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
2012 Standout
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
2005 Standout
Beneficial Effects of Fenofibrate to Improve Endothelial Dysfunction and Raise Adiponectin Levels in Patients With Primary Hypertriglyceridemia
2005
Role of Endothelial Dysfunction in Atherosclerosis
2004 Standout
Reciprocal Relationships Between Insulin Resistance and Endothelial Dysfunction
2006 Standout
Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss
2005 Standout
AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update
2011
Diabetes and Endothelial Dysfunction: A Clinical Perspective
2001
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Management of growth hormone deficiency in adults
2007
Impact of Androgen Deprivation Therapy on Cardiovascular Disease and Diabetes
2009
Cardiovascular Mortality After Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: RTOG 85-31
2008
Hypertriglyceridemic HyperapoB: The Unappreciated Atherogenic Dyslipoproteinemia in Type 2 Diabetes Mellitus
2001
Management of diabetes and associated cardiovascular risk factors in seven countries: a comparison of data from national health examination surveys
2010
Current Status of Platinum-Based Antitumor Drugs
1999 Standout
New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes
2016
Relationship between Disease-Related Morbidity and Biochemical Markers of Activity in Patients with Acromegaly
2005
Hydrolyzed Infant Formula and Early β-Cell Autoimmunity
2014
Increased Cardiovascular Risk in Hypertriglyceridemic Patients With Statin-Controlled LDL Cholesterol
2018
Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity
2016 Standout
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
2018 Standout
Advances in the Treatment of Prolactinomas
2006
Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk
2010
Once-Weekly Semaglutide in Adults with Overweight or Obesity
2021 Standout
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
2020 Standout
Changes in Bone Mineral Density, Lean Body Mass and Fat Content as Measured by Dual Energy X-Ray Absorptiometry in Patients With Prostate Cancer Without Apparent Bone Metastases Given Androgen Deprivation Therapy
2002
Diabetes in older people: new insights and remaining challenges
2014
Prevalence of and Risk Factors for Diabetic Macular Edema in the United States
2014
BICALUTAMIDE 150 MG MAINTAINS BONE MINERAL DENSITY DURING MONOTHERAPY FOR LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCER
2004
Glycemic Goals in Diabetes: Trade-off Between Glycemic Control and Iatrogenic Hypoglycemia
2014
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Adverse events associated with hormonal therapy for prostate cancer.
2005
Protein Glycoengineering Enabled by the Versatile Synthesis of Aminooxy Glycans and the Genetically Encoded Aldehyde Tag
2011 StandoutNobel
AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update
2011
Bicalutamide Monotherapy Versus Leuprolide Monotherapy for Prostate Cancer: Effects on Bone Mineral Density and Body Composition
2004
Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia
2012 Standout
Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes
2013
Cardiovascular safety of sulfonylureas: a meta‐analysis of randomized clinical trials
2013
MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
2019
Prescribed drugs containing nitrogen heterocycles: an overview
2020 Standout
Treatment of Periodontitis and Endothelial Function
2007 Standout
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Works of Marc Evans being referenced
The Impact of Treatment Noncompliance on Mortality in People With Type 2 Diabetes
2012
Pioglitazone in Clinical Practice: Where Are We Now?
2012
Long‐term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas
2005
Evaluation of Insulin Use and Value for Money in Type 2 Diabetes in the United Kingdom
2013
Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study
2010
Lixisenatide as add-on therapy to basal insulin
2013
The Effects of Induced Hypogonadism on Arterial Stiffness, Body Composition, and Metabolic Parameters in Males with Prostate Cancer
2001
Effects of GH replacement on endothelial function and large‐artery stiffness in GH‐deficient adults: a randomized, double‐blind, placebo‐controlled study
2002
Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus—An effect probably mediated by direct platelet PPARγ activation
2007
Effects of insulin lispro and chronic vitamin C therapy on postprandial lipaemia, oxidative stress and endothelial function in patients with type 2 diabetes mellitus
2003
The influence of the Pro12Ala mutation of the PPAR‐gamma receptor gene on metabolic and clinical characteristics in treatment‐naïve patients with type 2 diabetes
2002
The Effects of Depot Long-Acting Somatostatin Analog on Central Aortic Pressure and Arterial Stiffness in Acromegaly
2003
Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs
2011
What Next After Metformin? Thinking Beyond Glycaemia: Are SGLT2 Inhibitors the Answer?
2019
Clinical Effectiveness of Biphasic Insulin Aspart 30:70 Versus Biphasic Human Insulin 30 in UK General Clinical Practice: A Retrospective Database Study
2011
Insulin Resistance and inflammation—A Further Systemic Complication of COPD
2007
Ciprofibrate Therapy Improves Endothelial Function and Reduces Postprandial Lipemia and Oxidative Stress in Type 2 Diabetes Mellitus
2000
Mortality and Other Important Diabetes-Related Outcomes With Insulin vs Other Antihyperglycemic Therapies in Type 2 Diabetes
2013
What Next after Metformin? A Retrospective Evaluation of the Outcome of Second-Line, Glucose-Lowering Therapies in People with Type 2 Diabetes
2012
Endothelial dysfunction in hypopituitary adults with growth hormone deficiency
1999
An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin
2017
Phase II trial of carboplatin in advanced malignant melanoma.
1987
Long-Term Remission Following Withdrawal of Dopamine Agonist Therapy in Subjects With Microprolactinomas
2005